Clinical Trial Update: Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated a sequence of melphalan with autologous stem cell transplant followed by bortezomib and dexamethasone in patients with previously untr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• Alkeran (melphalan) (melphalan)
• Decadron (dexamethasone) (dexamethasone)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2016-08-10